Form 4: Aurinia COO Donley Reports Share Transactions

Aurinia Pharmaceuticals' Chief Operating Officer, Matthew Maxwell Donley, reported the acquisition of 54,166 common shares from a performance award and the disposition of 42,787 shares for tax withholding.

Summary

• Matthew Maxwell Donley, Chief Operating Officer of Aurinia Pharmaceuticals Inc. (AUPH), reported changes in his beneficial ownership of common stock.
• On January 2, 2026, Donley acquired 54,166 common shares as part of a performance award, which brought his beneficial ownership to 734,631 shares.
• On the same date, Donley disposed of 42,787 common shares at a price of $15.95 per share to satisfy tax withholding obligations upon the vesting of performance awards.
• Following these transactions, Donley's beneficial ownership stands at 695,801 common shares.
• The performance award vests in two equal annual installments on December 31, 2025, and December 31, 2026.
• The reported beneficial ownership also includes 2,500 common shares acquired on May 30, 2025, and 1,457 common shares acquired on November 28, 2025, through the Issuer's 2021 Employee Share Purchase Plan.

Sentiment

Score: 7

Explanation: The filing reflects routine insider transactions related to equity compensation. The acquisition of shares via a performance award is generally positive as it aligns management's interests with shareholders, while the disposition for tax purposes is a standard practice.

Positives

• The Chief Operating Officer acquired 54,166 common shares through a performance award, indicating continued equity incentive alignment with company performance.
• The performance award structure, with vesting in two equal annual installments, suggests a long-term retention and incentive strategy for key management.

Negatives

• The disposition of 42,787 shares for tax withholding, while a standard practice, represents a reduction in direct shareholding.

Future Outlook

The performance award vesting schedule, with installments on December 31, 2025, and December 31, 2026, indicates a continued long-term incentive structure for the Chief Operating Officer.

Industry Context

This filing is a routine insider transaction report and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders benefit from the continued alignment of the Chief Operating Officer's interests with company performance through equity compensation.

Next Steps

• The remaining installment of the performance award is scheduled to vest on December 31, 2026.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions for Aurinia Pharmaceuticals' COO, Matthew Maxwell Donley. The acquisition of shares stems from a performance award, aligning management's incentives with long-term company performance, which is a positive. The subsequent disposition of shares for tax withholding is a standard practice and does not indicate a change in sentiment. The overall impact on the company's fundamentals or strategic direction is neutral, suggesting a 'hold' recommendation based solely on this filing.

Keywords

Aurinia Pharmaceuticals, AUPH, Form 4, insider trading, beneficial ownership, stock transactions, COO, Matthew Donley, performance award, equity compensation, tax withholding